Princy Kumar

Research interests

Publications

• Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19

  JAMA · 2021 · https://doi.org/10.1001/jama.2021.0202

• Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US

  JAMA Internal Medicine · 2020 · https://doi.org/10.1001/jamainternmed.2020.3596

• Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1711460

• Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence

  Clinical Infectious Diseases · 2018 · https://doi.org/10.1093/cid/ciy171

• Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

  Gastroenterology · 2015 · https://doi.org/10.1053/j.gastro.2015.05.010

• Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

  The Journal of Infectious Diseases · 2014 · https://doi.org/10.1093/infdis/jiu051

• Guidelines for Improving Entry Into and Retention in Care and Antiretroviral Adherence for Persons With HIV: Evidence-Based Recommendations From an International Association of Physicians in AIDS Care Panel

  Annals of Internal Medicine · 2012 · https://doi.org/10.7326/0003-4819-156-11-201206050-00419

• Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

  The Journal of Infectious Diseases · 2012 · https://doi.org/10.1093/infdis/jis750

• Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials

  Clinical Infectious Diseases · 2010 · https://doi.org/10.1086/650002

• Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

  The Lancet · 2010 · https://doi.org/10.1016/s0140-6736(09)62041-9

• Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

  AIDS · 2009 · https://doi.org/10.1097/qad.0b013e32832cbcc2

• Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

  New England Journal of Medicine · 2008 · https://doi.org/10.1056/nejmoa0708978

• Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

  New England Journal of Medicine · 2008 · https://doi.org/10.1056/nejmoa0708975

• Highly Active Antiretroviral Therapy Decreases Mortality and Morbidity in Patients with Advanced HIV Disease

  Annals of Internal Medicine · 2001 · https://doi.org/10.7326/0003-4819-135-1-200107030-00005

• Expression of Chemokine Receptors CXCR4 and CCR5 in HIV-1-Infected and Uninfected Individuals

  The Journal of Immunology · 1998 · https://doi.org/10.4049/jimmunol.161.6.3195

• Role of Fas Ligand and Receptor in the Mechanism of T-Cell Depletion in Acquired Immunodeficiency Syndrome: Effect on CD4+ Lymphocyte Depletion and Human Immunodeficiency Virus Replication

  Blood · 1997 · https://doi.org/10.1182/blood.v89.4.1357

Current projects

No projects listed.